Genetic
Strimvelis
Strimvelis is a genetic therapy with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
GENETIC
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_4
1
25%
Phase Distribution
0
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution1 total trials
Phase 4Post-market surveillance
1(100.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(1)
Terminated(1)
Other(1)
Detailed Status
Enrolling by invitation1
Withdrawn1
unknown1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 41 (100.0%)
Trials by Status
enrolling_by_invitation125%
withdrawn125%
unknown125%
completed125%
Recent Activity
0 active trials
Showing 4 of 4
withdrawnphase_4
Retroviral Insertion Site Methodology Study
NCT03311074
unknown
Methodology Study of Retroviral Insertion Site Analysis in Strimvelis Gene Therapy
NCT04959890
enrolling_by_invitation
Strimvelis Registry Study to Follow-up Patients With Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID)
NCT03478670
completed
Evaluating the Effectiveness of STRIMVELIS Risk Minimization Measures (RMMs)
NCT03232203
Clinical Trials (4)
Showing 4 of 4 trials
NCT03311074Phase 4
Retroviral Insertion Site Methodology Study
NCT04959890
Methodology Study of Retroviral Insertion Site Analysis in Strimvelis Gene Therapy
NCT03478670
Strimvelis Registry Study to Follow-up Patients With Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID)
NCT03232203
Evaluating the Effectiveness of STRIMVELIS Risk Minimization Measures (RMMs)
All 4 trials loaded
Drug Details
- Intervention Type
- GENETIC
- Total Trials
- 4